ArticleJournal of the American Heart Association2025
Modifiable Factors and 10-Year and Lifetime Risk of Cardiovascular Disease in Adults With New-Onset Diabetes: The Kailuan Cohort Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdults with newly diagnosed diabetes are at elevated risk of cardiovascular disease (CVD). However, the extent to which optimizing modifiable lifestyle and clinical factors can mitigate this risk remains insufficiently assessed across both short- and long-term risk periods.
methodsThis study analyzed 12 222 participants from the Kailuan cohort (2006-2016) who developed new-onset diabetes and were free of baseline CVD. Modifiable risk factors were assessed using the Life's Essential 8 algorithm, including physical activity, nicotine exposure, dietary health, sleep duration, body mass index, blood pressure, blood glucose, and lipid levels. Participants were followed through 2020 for CVD incidence. Ten-year and lifetime (ages 25-85) CVD risks were estimated using Fine-Gray competing risks models.
resultsDuring a median follow-up of 7.6 years, 1371 participants experienced CVD events. Only 7.3% of individuals had ≥4 modifiable risk factors at favorable levels at baseline. The 10-year CVD risk decreased from 16.01% to 6.11% as favorable factors increased from ≤1 to ≥4; lifetime CVD risk declined from 55.16% to 26.70%. After adjusting for unmodifiable covariates, participants with 2, 3, and ≥4 favorable factors had 13% (hazard ratio [HR], 0.87 [95% CI, 0.77-0.98]), 31% (HR, 0.69 [95% CI, 0.59-0.80]), and 65% (HR, 0.35 [95% CI, 0.26-0.47]) lower 10-year CVD risks, respectively, compared with those with ≤1 favorable factor. Lifetime CVD risk reductions were 9% (HR, 0.91 [95% CI, 0.81-1.03]), 27% (HR, 0.73 [95% CI, 0.62-0.85]), and 61% (HR, 0.39 [95% CI, 0.29-0.52]), respectively.
conclusionsImproving modifiable risk factors is associated with reduced short- and long-term CVD risk in adults with new-onset diabetes, underscoring the importance of proactive lifestyle interventions in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.